Zi Shen Huo Luo Formula Prevents Aldosterone-Induced Cardiomyocyte Hypertrophy and Cardiac Fibroblast Proliferation by Regulating the Striatin-Mediated MR/EGFR/ERK Signaling Pathway

Figure 3

Effects of ZSHLF on the cardiomyocyte surface area and the proliferation and hydroxyproline secretion of cardiac fibroblasts. Cardiomyocytes and cardiac fibroblasts in the control group were pretreated with blank serum. In the aldosterone (ALD) group, cardiomyocytes and cardiac fibroblasts were pretreated with blank serum, and the cardiomyocytes were then incubated with 10⁻⁹ mol/l aldosterone for 30 min, and the cardiac fibroblasts were incubated with 10⁻⁷ mol/l aldosterone for 30 min. In the ZSHLF group, cardiomyocytes and cardiac fibroblasts were pretreated with 10% ZSHLF-containing serum for 2 h and then incubated with aldosterone, as described for the ALD group. (a) Cells subjected to immunofluorescent assays using DAPI (blue) and FITC (green). (b) Cardiomyocyte surface area (relative to that in the control group) was determined by α-actinin immunofluorescence staining. (c) OD values of cardiac fibroblasts were detected by a CCK-8 assay. (d) Hydroxyproline content in the culture supernatant of cardiac fibroblasts. vs. the blank group; and vs. the ALD group.

(a)

(b)

(c)

(d)